Drug Trial Radar · NCT04940390
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Last checked: Nov 19, 2026Latest source record: Nov 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,591
Actual
Start
Jun 30, 2021
Primary completion
Oct 13, 2022
Study completion Oct 26, 2022
Sponsor
- Lead sponsor
- Satsuma Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study STS101-007 is a randomized, double-blind, parallel group, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of single doses of STS101 (dihydroergotamine nasal powder) in the acute treatment of migraine.
Conditions
- Migraine
- Migraine With Aura
- Migraine Without Aura
Interventions
DihydroergotamineDrug
Dihydroergotamine is a semi-synthetic derivative of ergotamine tartrate.
PlaceboDrug
Placebo for STS101
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Freedom From Migraine Headache Pain at 2 Hours Post DoseTime frame: 2 Hours Post-Dose
- Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post DoseTime frame: 2 Hours Post-Dose
Locations
127 sites in 1 country. Site status is shown where the registry gives one.
MD First Research
Chandler, Arizona
Elite Clinical Studies
Phoenix, Arizona
Alliance For Multispecialty Research
Tempe, Arizona
Cognitive Clinical Trials, LLC
Tempe, Arizona
Clinedge, LLC
Tucson, Arizona
ERG Clinical
Little Rock, Arkansas
Hope Clinical Research
Canoga Park, California
Wr-Pri, Llc
Encino, California
Neuro-Pain Medical Center Ince
Fresno, California
Estudy Site - La Mesa
La Mesa, California
Wr-Pri Llc
Los Alamitos, California
Downtown LA Research Center
Los Angeles, California
Clinical Research Institute
Los Angeles, California
Wr-Pri Llc
Newport Beach, California
Artemis Institute for Clinical Research - San Diego
San Diego, California
WR-MCCR
San Diego, California
Acclaim Clinical Research
San Diego, California
National Research Institute, A Clinical Research Organization
Santa Ana, California
Alpine Clinical Research Center, Inc
Boulder, Colorado
Clinedge, LLC
Cromwell, Connecticut
Neurology Offices of South Florida
Boca Raton, Florida
Velocity Clinical Research, Hallendale Beach
Hallandale, Florida
Infinity Clinical Research, LLC
Hollywood, Florida
Elite Research Network, LLC a Florida LLC
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida
Elite Research Network LLC a Florida LLC
Jupiter, Florida
Multi-Specialty Research Associates
Lake City, Florida
Clinicloud
Maitland, Florida
Next Phase Research
Miami, Florida
Applemed Research Group
Miami, Florida
Biotech Pharmaceuticals Group LLC
Miami, Florida
Novel Clinical Research Center LLC
Miami, Florida
Floridian Research
Miami, Florida
Behavioral Clinical Research
North Miami, Florida
Accel-Orange City
Orange City, Florida
CNS Health Care Orlando
Orlando, Florida
Complete Health Research
Ormond Beach, Florida
Oveido Medical Research
Oviedo, Florida
Santos Research Center
Tampa, Florida
VICIS Clinical Research, Inc
Tampa, Florida
Showing 40 of 127 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.